CTHIn ForceLegislation
National Health (Pharmaceutical Benefits) Regulations 2017
70Method for determining weighted average disclosed price of listed brand of pharmaceutical item
Start here
Get a plain-English read of 70
Turn the raw legal text into a practical explanation grounded in National Health (Pharmaceutical Benefits) Regulations 2017.
#### 70 Method for determining weighted average disclosed price of listed brand of pharmaceutical item
(1) This Subdivision is made for the purposes of subsection 99ADB(6) of the Act.
(2) Sections 71 to 81 prescribe the method for determining the weighted average disclosed price of a listed brand of a pharmaceutical item in respect of a data collection period for the listed brand.
(3) When using the method, the Minister may disregard information provided under section 85 for a data collection period if the information is incomplete.
> Note 1: Section 99ADA of the Act provides that Division 3B (Price disclosure) of Part VII of the Act does not apply to brands of exempt items.
> Note 2: Subdivision C prescribes information that must not be taken into account in determining a weighted average disclosed price.